Stocks News

LAST PRICE
17.9500
TODAY'S CHANGE (%)
Trending Up1.8700 (11.6294%)

Bid / Lots
16.5000/ 4
Ask / Lots
17.5000/ 1
Open / Previous Close
15.2200 / 16.0800
Day Range
Low 15.0700
High 17.9999
52 Week Range
Low 4.1100
High 21.2500
Volume
124,826
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Forte Biosciences to Host R&D Day December 3, 2024, from 9:00AM ET on Monday Nov 25, 2024 by Dow Jones
  9:00AM ET on Monday Nov 25, 2024 by Dow Jones
  Companies Mentioned: FBRX
  
  Forte Biosciences to Host R&D Day December 3, 2024
  DALLAS--(BUSINESS WIRE)--November 25, 2024--
  Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3, 2024 at 4:30 p.m. ET.
Nov 20, 2024
- *DJ Forte Biosciences: Private Placement Announced Earlier Includes Sale of 4.93M Shrs for $5.55 Each, and Sale of 4.62M Pre-Funded Warrants for $5.55 Each, from 4:25PM ET on Wednesday Nov 20, 2024 by Dow Jones
  4:25PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: FBRX
- DJ Forte Biosciences More Than Doubles on $53M Private Placement, from 1:08PM ET on Wednesday Nov 20, 2024 by Dow Jones
  1:08PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: FBRX
  
  By Josh Beckerman
  
  Forte Biosciences shares more than doubled after the company announced a $53 million private placement to support the advancement of FB102 across autoimmune indications.
- Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications, from 9:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  9:00AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: FBRX
  
  Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
  DALLAS--(BUSINESS WIRE)--November 20, 2024--
Nov 15, 2024
- DJ Forte Biosciences Is Maintained at Buy by Chardan Capital, from 5:35PM ET on Friday Nov 15, 2024 by Dow Jones
  5:35PM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: FBRX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/FBRX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 15, 2024 17:35 ET (22:35 GMT)

Today
- DJ IN8bio Price Target Announced at $8.00/Share by HC Wainwright & Co., from 14 hours ago by Dow Jones
  14 hours ago by Dow Jones
  Companies Mentioned: INAB
Yesterday
- IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting, from 7:00AM ET on Monday Nov 25, 2024 by Dow Jones
  7:00AM ET on Monday Nov 25, 2024 by Dow Jones
  Companies Mentioned: INAB
Nov 22, 2024
- DJ MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 -- Barrons.com, from 12:25PM ET on Friday Nov 22, 2024 by Dow Jones
  12:25PM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: MSTR, HOTH, ACXP, ENLV
Nov 21, 2024
- DJ Lisata Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co., from 6:47AM ET on Thursday Nov 21, 2024 by Dow Jones
  6:47AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: LSTA
Nov 20, 2024
- DJ Acurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin Investment, from 3:12PM ET on Wednesday Nov 20, 2024 by Dow Jones
  3:12PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: ACXP
- Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset, from 7:01AM ET on Wednesday Nov 20, 2024 by PR Newswire
  7:01AM ET on Wednesday Nov 20, 2024 by PR Newswire
  Companies Mentioned: ACXP
- Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset, from 7:01AM ET on Wednesday Nov 20, 2024 by Dow Jones
  7:01AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: ACXP
Nov 19, 2024
- Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year', from 8:30AM ET on Tuesday Nov 19, 2024 by Dow Jones
  8:30AM ET on Tuesday Nov 19, 2024 by Dow Jones
  Companies Mentioned: LSTA
Nov 18, 2024
- Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update, from 7:00AM ET on Monday Nov 18, 2024 by Dow Jones
  7:00AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: ACXP
Nov 14, 2024
- DJ Acurx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co., from 7:07AM ET on Thursday Nov 14, 2024 by Dow Jones
  7:07AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: ACXP

Forte Biosciences Inc
NASDAQ:FBRXUnited States

Search Criteria

Yesterday

Forte Biosciences to Host R&D Day December 3, 2024, from 9:00AM ET on Monday Nov 25, 2024 by Dow Jones

Nov 20, 2024

*DJ Forte Biosciences: Private Placement Announced Earlier Includes Sale of 4.93M Shrs for $5.55 Each, and Sale of 4.62M Pre-Funded Warrants for $5.55 Each, from 4:25PM ET on Wednesday Nov 20, 2024 by Dow Jones

DJ Forte Biosciences More Than Doubles on $53M Private Placement, from 1:08PM ET on Wednesday Nov 20, 2024 by Dow Jones

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications, from 9:00AM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 15, 2024

DJ Forte Biosciences Is Maintained at Buy by Chardan Capital, from 5:35PM ET on Friday Nov 15, 2024 by Dow Jones

Peers Headlines

Today

DJ IN8bio Price Target Announced at $8.00/Share by HC Wainwright & Co., from 14 hours ago by Dow Jones

Yesterday

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting, from 7:00AM ET on Monday Nov 25, 2024 by Dow Jones

Nov 22, 2024

DJ MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 -- Barrons.com, from 12:25PM ET on Friday Nov 22, 2024 by Dow Jones

Nov 21, 2024

DJ Lisata Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co., from 6:47AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 20, 2024

DJ Acurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin Investment, from 3:12PM ET on Wednesday Nov 20, 2024 by Dow Jones

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset, from 7:01AM ET on Wednesday Nov 20, 2024 by PR Newswire

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset, from 7:01AM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 19, 2024

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year', from 8:30AM ET on Tuesday Nov 19, 2024 by Dow Jones

Nov 18, 2024

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update, from 7:00AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 14, 2024

DJ Acurx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co., from 7:07AM ET on Thursday Nov 14, 2024 by Dow Jones